CD274 and cancer: Considering whole-exome sequencing (WES) and gene expression profiling (GEP) data obtained from fresh surgical specimens taken from cancer patients, Project High-tech Omics-based Patient Evaluation (HOPE) classified TIM immunological status into 4 types according to the expression level of PD-L1 and CD8B genes; i.e., type A TIMs express PD-L1+ CD8B+; type B TIMs express PD-L1+ CD8B−; type C TIMs express PD-L1− CD8B−; and type D TIMs express PD-L1− CD8B+.